Antioxidant treatment for heart failure: Friend or foe?

QJM: An International Journal of Medicine

Volumn 102, Issue 5, 2009, Pages 305-310

  Thomson, M J ^a   Frenneaux, M P ^b   Kaski, J C ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALLOPURINOL; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUTATHIONE PEROXIDASE; HYDRALAZINE; ISOSORBIDE MONONITRATE; NITRIC OXIDE; PLACEBO; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SPIRONOLACTONE; SUPEROXIDE DISMUTASE;

CARDIOMYOPATHY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DISEASE CONTROL; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TARGETING; ENDOTHELIUM CELL; GENETIC TRANSCRIPTION; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HUMAN; MEDITERRANEAN DIET; MONOTHERAPY; MORBIDITY; MORTALITY; MUSCLE CELL; NONHUMAN; OXIDATION REDUCTION POTENTIAL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE;

ANIMALS; ANTIOXIDANTS; HEART FAILURE; HUMANS; ISOENZYMES; MICE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS; VITAMIN E;

EID: 65449172088     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcn160     Document Type: Review

References (54)

1. Landmesser U, Spiekermann S, Dikalov S, Tatge H, Wilke R, Kohler C, et al. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure. Role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 2002; 106 3073-8.
2. Münzel T, Harrison DG. Increased superoxide in heart failure. A baroreflex gone awry. Circulation 1999; 100: 216-18.
3. Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular diseases: molecular mechanism and pathophysiological Implications. J Physiol 2004; 555:589-606.
4. Murdoch CE, Grieve DJ, Cave AC, Looi YH, Shah AM. NADPH oxidase and heart failure. Curr Opin Pharmacol 2006; 6:148-53.
5. Singal PK, Beamish RE, Dhalla NS. Potential oxidative pathways of catecholamines in the formation of lipid peroxides and genesis of heart disease. Adv Exp Med Biol 1983; 161:391-401.
6. Habib FM, Springall DR, Davies GJ, Oakley CM, Yacoub MH, Polak JM. Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet 1996; 347:1151-5.
7. Grieve D, Shah A. Oxidative stress in heart failure: More than just damage. Eur Heart J 2003; 24:2161-3.
8. Ozawa T, Tanaka M, Sugiyama S, Hattori K, Ito T, Ohno K, et al. Multiple mitochondrial DNA deletions exist in cardiomyocytes of patients with hypertrophic or dilated cardiomyopathy. Biochem Biophys Res Commun 1990; 170:830-36.
9. Mak S, Newton GE. The oxidative stress hypothesis of congestive heart failure. Radical thoughts. Chest 2001; 120:2035-46.
10. Liu H, Colavitti R, Rovira II, Finkel T. Redox-dependent transcriptional regulation. Circ Res 2005; 97:967-74.
11. Chandra M, Surendra K, Kapoor RK, Ghatak A, Kaur G, Pandey NR, et al Oxidant stress mechanisms in heart failure. Boll Chim Farm 2000; 139:149-52.
12. Harsdorf R, Li P-F, Dietz R. Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis. Circulation 1999; 99 2934-41.
13. Benjamin IJ, Schneider MD. Learning from failure: Congestive heart failure in the postgenomic age. J Clin Invest 2005; 115 495-9.
14. Shiomi T, Tsutsui H, Matsusaka H, Murakami K, Hayashidani S, Ikeuchi M, et al. Overexpression of glutathione peroxidase prevents left ventricular remodelling and failure after myocardial infarction in mice. Circulation 2004; 109:544-9.
15. Adamy C, Mulder P, Khouzami L, Andrieu-abadie N, Defer N, Candiani G, et al. Neutral sphingomyelinase inhibition participates to the benefits of N-acetylcysteine treatment in post-myocardial infarction failing heart rats. J Mol Cell Cardiol 2007; 43:344-3.
16. Von Haehling S, Jankowska EA, Anker SD. Tumour necrosis factor-alpha and the failing heart: Pathophysiology and therapeutic implications. Basic Res Cardiol 2004; 99:18-28.
17. Carr A, Frei B. Does vitamin C act as a pro-oxidant under physiological conditions? The FASEB J 1999; 13:1007-24.
18. Ellis GR, Anderson RA, Lang D, Blackman DJ, Morris RHK, Morris-Thurgood J, et al. Neutrophil superoxide anion-generating capacity, endothelial function and oxidative stress in chronic heart failure effects: Of short-term and long-term vitamin C therapy. J Am Coll Cardiol 2000; 36:1474-82.
19. Dutka D, Pitt M, Pagano D, Mongillo M, Gathercole D, Bonser RS, et al Myocardial glucose transport and utilisation in patients with type 2 diabetes mellitus, left ventricular dysfunction, and coronary artery disease. J Am Coll Cardiol 2006; 48:2225-31.
20. Konya C, Ferdinandy P. Vitamin C: New role of the old vitamin in the cardiovascular system? B J Pharmacol 2006; 147:125-7.
21. Heller R, Unbehaun A, Schellenberg B, Mayer B, Werner-Felmayer G, Werner ER. L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilisation of tetrahydrobiopterin. J Biol Chem 2001; 276:40-7.
22. Libby P, Aikawa M. Vitamin C, collagen, and cracks in the plaque. Circulation 2002; 105:1396-8.
23. Saeed RW, Peng T, Metz CN. Ascorbic acid blocks the growth inhibitory effect of tumour necrosis factor-α on endothelial cells. Exp Biol Med 2003; 228:855-65.
24. Piccirillo G, Nocco M, Moisè A, Lionetti M, Naso C, di Carlo S, et al. Influence of vitamin c on baroreflex sensitivity in chronic heart failure. Hypertension 2003; 41:1240-5.
25. Nightingale AK, Blackman DJ, Field R, Glover NJ, Pegge N, Mumford C, et al. Role of nitric oxide and oxidative stress in baroreceptor dysfunction in patients with chronic heart failure. Clinl Sci 2003; 104:529-35.
26. Esposito K, Giugliano D. Diet and inflammation: A link to metabolic syndrome and cardiovascular diseases. Eur Heart J 2006; 27 15-20.
27. de Lorgeril M, Salen P, Martin J-L, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: Final report of the lyon diet heart study. Circulation 1999; 99:779-85.
28. The Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 2000; 342:154-60.
29. GISSI Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354 447-55.
30. Kuller LH. A time to stop prescribing antioxidant vitamins to prevent and treat heart disease? Arterioscler Thromb Vasc Biol 2001; 21 1253.
31. Steinberg D, Witztum JL. Current perspective. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation 2002; 105:2107.
32. Hare JM. Nitroso-redox balance in the cardiovascular system. N Eng J Med 2004; 351:2112-14.
33. Saraiva RM, Minhas KM, Raju SVY, Barouch LA, Pitz E, Schuleri KH, et al. Deficiency of neuronal nitric oxide synthase increases mortality and cardiac remodeling after myocardial infarction. Role of the nitroso-redox equilibrium. Circulation 2005; 112:3415-22.
34. Datta B, Tufnell-Barrett T, Bleasdale RA, Jones CJH, Beeton I, Paul V, et al. Red blood cell nitric oxide as an endocrine vasoregulator. a potential role in congestive heart failure. Circulation 2004; 109:1339-42.
35. Singel DJ, Stamler JS. Blood traffic control. Red blood cell vasodilation: Nitric oxide and haemoglobin help to match blood flow to metabolic demand. Nature 2004; 430:297.
36. Stamler JS, Lamas S, Fang FC. Nitrosylation: The prototypic redox-based signaling mechanism. Cell 2001; 106:675-83.
37. Damy T, Ratajczak P, Shah A, Camors E, Marty I, Hasenfuss G, et al Increased neuronal nitric oxide synthase-derived NO production in the failing human heart. Lancet 2004; 363:1365-7.
38. McNamara DM, Holubkov R, Postava L, Ramani R, Janosko K, Mathier M, et al. Effect of the ASP298 variant of endothelial nitric oxide synthase on survival for patients with congestive heart failure. Circulation 2003; 107:1598-1602.
39. Drexler H. Nitric oxide synthases in the failing human heart: A double-edged sword? Circulation 1999; 99:2972-5.
40. Heymes C, Vanderheyden M, Bronzwaer JGF, Shah AM, Paulus WJ. Endomyocardial nitric oxide synthase and left ventricular preload reserve in dilated cardiomyopathy. Circulation 1999; 99 3009-16.
41. Pacher P, Schulz R, Liaudet L, Szabo C. Nitrosative stress and pharmacological modulation of heart failure. Trends Pharmacol Sci 2005; 26:302-10.
42. Keidar S, Gamliel-Lazarovich A, Kaplan M, Pavlotzky E, Hamoud S, Hayek T, et al. Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients. Circulation Res 2005; 97:946-53.
43. Johar S, Cave AC, Narayanapanicker A, Grieve DJ, Shah AM. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB 2006; 20:1546-8.
44. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351:2049-57.
45. The HOPE and HOPE-TOO Trial Investigators. Effects of long-term vitamin E supplementation on cardiovascular events and cancer. A randomised controlled trial. JAMA 2005; 293:1338-47.
46. Levantesi G, Macchia A, Marfisi RM, Franzosi MG, Maggioni AP, Nicolosi GL, et al.; GISSI-Prevenzione Investigators. Metabolic syndrome and risk of cardiovascular events after myocardial infarction. J Am Coll Cardiol 2005; 46:277-83.
47. Miller III R, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: High dose vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142:37-46.
48. Heinecke JW. Is the emperor wearing clothes? Clinical trials of vitamin E and the LDL oxidation hypothesis. Arterioscler Thromb Vasc Biol 2001; 21:1261-4.
49. Brown B, Crowley J. Is there any hope for vitamin E? JAMA 2005; 293:1387-90.
50. Rössig L, Hoffmann J, Hugel B, Mallat Z, Haase A, Freyssinet JM, et al. Vitamin C inhibits endothelial cell apoptosis in congestive heart failure. Circulation 2001; 104:2182-7.
51. Roberto F, Guardigli G, Mele D, Percoco GF, Ceconi C, Curello S. Oxidative stress during myocardial ischaemia and heart failure. Curr Pharm Des 2004; 14:1699-1711.
52. Nightingale A, Crilley J, Pegge N, Boehm E, Mumford C, Taylor D, et al. Chronic oral ascorbic acid therapy worsens skeletal muscle metabolism in patients with chronic heart failure. Eur J Heart Failure 2006; 9:287-91.
53. Shishehbor MH, Brennan M-L, Aviles RJ, Fu X, Penn MS, Sprecher DL, et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 2003; 108:426-31.
54. Malinski T. Understanding nitric oxide physiology in the heart: A nanomedical approach. Am J Cardiol 2005; 96:13-24.